Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 111
Filtrar
Más filtros

Tipo del documento
Intervalo de año de publicación
1.
Cell Mol Life Sci ; 79(6): 341, 2022 Jun 04.
Artículo en Inglés | MEDLINE | ID: mdl-35660973

RESUMEN

In Lesch-Nyhan disease (LND), deficiency of the purine salvage enzyme hypoxanthine guanine phosphoribosyl transferase (HGprt) leads to a characteristic neurobehavioral phenotype dominated by dystonia, cognitive deficits and incapacitating self-injurious behavior. It has been known for decades that LND is associated with dysfunction of midbrain dopamine neurons, without overt structural brain abnormalities. Emerging post mortem and in vitro evidence supports the hypothesis that the dopaminergic dysfunction in LND is of developmental origin, but specific pathogenic mechanisms have not been revealed. In the current study, HGprt deficiency causes specific neurodevelopmental abnormalities in mice during embryogenesis, particularly affecting proliferation and migration of developing midbrain dopamine (mDA) neurons. In mutant embryos at E14.5, proliferation was increased, accompanied by a decrease in cell cycle exit and the distribution and orientation of dividing cells suggested a premature deviation from their migratory route. An abnormally structured radial glia-like scaffold supporting this mDA neuronal migration might lie at the basis of these abnormalities. Consequently, these abnormalities were associated with an increase in area occupied by TH+ cells and an abnormal mDA subpopulation organization at E18.5. Finally, dopaminergic innervation was disorganized in prefrontal and decreased in HGprt deficient primary motor and somatosensory cortices. These data provide direct in vivo evidence for a neurodevelopmental nature of the brain disorder in LND. Future studies should not only focus the specific molecular mechanisms underlying the reported neurodevelopmental abnormalities, but also on optimal timing of therapeutic interventions to rescue the DA neuron defects, which may also be relevant for other neurodevelopmental disorders.


Asunto(s)
Síndrome de Lesch-Nyhan , Animales , Modelos Animales de Enfermedad , Dopamina/metabolismo , Neuronas Dopaminérgicas/metabolismo , Hipoxantina Fosforribosiltransferasa/genética , Hipoxantina Fosforribosiltransferasa/metabolismo , Síndrome de Lesch-Nyhan/genética , Síndrome de Lesch-Nyhan/metabolismo , Mesencéfalo/metabolismo , Ratones
3.
J Viral Hepat ; 24(9): 776-788, 2017 09.
Artículo en Inglés | MEDLINE | ID: mdl-28218976

RESUMEN

We investigated innate immune gene expression in clinical phases of chronic hepatitis B infection, including immune tolerant (IT), immune active (IA), inactive carrier (IC) and hepatitis B e antigen (HBeAg)-negative phases, as well as healthy controls. Expression levels of interferon types I, II and III, their receptor subunits, IRFs, TLRs and other IFN-induced genes in peripheral blood mononuclear cells were compared. Forty HBsAg-positive treatment-naïve subjects without co-infection with HIV, HCV or HDV were enrolled. To complement the viral load, the expression levels of 37 innate immune genes were measured by qPCR. The highest response of the innate immune system was observed in the IT and HBeAg-negative phases, and the IC phase had the lowest response; 31 of the 37 studied genes reached their maximum mRNA expression levels in the IT and HBeAg-negative phases, and the minimum expression levels of 23 genes were found in the IC phase. The highest mRNA expression levels of IFNs, IFN receptor subunits, IRFs and TLRs genes in all clinical phases were IFN-λ2 and 3, IFN-γR2, IRF7 and TLR7, and the lowest levels of mRNA expression were observed for IFN-α, IFN-λR1, IRF8 and TLR2. We conclude that innate immune response genes are expressed differentially among chronic HBV phases, and this difference may help to develop new precise and noninvasive methods to determine the progression of disease in chronic HBV patients.


Asunto(s)
Perfilación de la Expresión Génica , Virus de la Hepatitis B/inmunología , Hepatitis B Crónica/inmunología , Inmunidad Innata , Factores Inmunológicos/biosíntesis , Adolescente , Adulto , Femenino , Humanos , Factores Inmunológicos/genética , Leucocitos Mononucleares/inmunología , Masculino , Persona de Mediana Edad , ARN Mensajero/análisis , ARN Mensajero/genética , Reacción en Cadena en Tiempo Real de la Polimerasa , Adulto Joven
4.
J Viral Hepat ; 24(11): 917-926, 2017 11.
Artículo en Inglés | MEDLINE | ID: mdl-28414896

RESUMEN

Natural killer (NK) cells have long been thought of as a purely innate immune cell population, but increasing reports have described developmental and functional qualities of NK cells that are commonly associated with cells of the adaptive immune system. Of these features, the ability of NK cells to acquire functional qualities associated with immunological memory and continuous differentiation resulting in the formation of specific NK cell repertoires has recently been highlighted in viral infection settings. By making use of a unique cohort of monitored, at-risk intravenous drug users in this study, we were able to dissect the phenotypic and functional parameters associated with NK cell differentiation and NK cell memory in patients 3 years after acute HCV infection and either the subsequent self-clearance or progression to chronicity. We observed increased expression of cytolytic mediators and markers CD56bright and NKp46+ of NK cells in patients with chronic, but not self-limited HCV infection. Patients with a self-limited infection expressed higher levels of differentiation-associated markers CD57 and KIRs, and lower levels of NKG2A. A more extensively differentiated NK cell phenotype is associated with self-clearance in HCV patients, while the NK cells of chronic patients exhibited more naïve and effector NK cell phenotypic and functional characteristics. The identification of these distinct NK cell repertoires may shed light on the role NK cells play in determining the outcome of acute HCV infections, and the underlying immunological defects that lead to chronicity.


Asunto(s)
Diferenciación Celular , Hepacivirus/inmunología , Hepatitis C/inmunología , Hepatitis C/virología , Memoria Inmunológica , Células Asesinas Naturales/citología , Células Asesinas Naturales/inmunología , Adulto , Biomarcadores , Antígeno CD56/metabolismo , Diferenciación Celular/inmunología , Estudios de Cohortes , Citocinas/metabolismo , Femenino , Genotipo , Granzimas/metabolismo , Hepatitis C/metabolismo , Humanos , Inmunofenotipificación , Células Asesinas Naturales/metabolismo , Recuento de Linfocitos , Masculino , Persona de Mediana Edad , Receptores Gatillantes de la Citotoxidad Natural/metabolismo , Ligando Inductor de Apoptosis Relacionado con TNF/metabolismo , Carga Viral , Adulto Joven
5.
J Viral Hepat ; 24(11): 1023-1031, 2017 11.
Artículo en Inglés | MEDLINE | ID: mdl-28544398

RESUMEN

An abundance of noninvasive scores have been associated with fibrosis and hepatocellular carcinoma (HCC) development. We aimed to compare the prognostic ability of these scores in relation to liver histology in chronic hepatitis B (CHB) patients. Liver biopsies from treatment-naïve CHB patients at one tertiary care centre were scored by a single hepato-pathologist. Laboratory values at liver biopsy were used to calculate the PAGE-B, REACH-B, GAG-HCC, CU-HCC and FIB-4 scores. Any clinical event was defined as HCC development, liver failure, transplantation and mortality. HCC and mortality data were obtained from national database registries. Of 557 patients, 40 developed a clinical event within a median follow-up of 10.1 (IQR 5.7-15.9) years. The PAGE-B score predicted any clinical event (C-statistic.86, 95% CI: 0.80-0.92), HCC development (C-statistic .91) and reduced transplant-free survival (C-statistic .83) with good accuracy, also when stratified by ethnicity, antiviral therapy after biopsy or advanced fibrosis. The C-statistics (95% CI) of the REACH-B, GAG-HCC, CU-HCC and FIB-4 scores for any event were .70 (0.59-0.81), .82 (0.75-0.89), .73 (0.63-0.84) and.79 (0.69-0.89), respectively. The PAGE-B event risk assessment improved modestly when combined with the Ishak fibrosis stage (C-statistic .87, 95% CI: 0.82-0.93). The PAGE-B score showed the best performance in assessing the likelihood of developing a clinical event among a diverse CHB population over 15 years of follow-up. Additional liver histological characteristics did not appear to provide a clinically significant improvement.


Asunto(s)
Hepatitis B Crónica/epidemiología , Adulto , Biomarcadores , Biopsia , Causas de Muerte , Femenino , Hepatitis B Crónica/mortalidad , Hepatitis B Crónica/patología , Humanos , Estimación de Kaplan-Meier , Hígado/patología , Masculino , Persona de Mediana Edad , Países Bajos/epidemiología , Evaluación de Resultado en la Atención de Salud , Vigilancia de la Población , Pronóstico , Estudios Retrospectivos , Medición de Riesgo , Factores de Riesgo , Factores de Tiempo , Adulto Joven
6.
Clin Exp Immunol ; 185(1): 42-9, 2016 07.
Artículo en Inglés | MEDLINE | ID: mdl-26850369

RESUMEN

In humans, CD16 and CD56 are used to identify functionally distinct natural killer (NK) subsets. Due to ubiquitous CD56 expression, this marker cannot be used to distinguish between NK cell subsets in chimpanzees. Therefore, functional analysis of distinct NK subsets during hepatitis C virus (HCV) infection has never been performed in these animals. In the present study an alternative strategy was used to identify four distinct NK subsets on the basis of the expression of CD16 and CD94. The expression of activating and inhibiting surface receptors showed that these subsets resemble human NK subsets. CD107 expression was used to determine degranulation of the different subsets in naive and HCV-infected chimpanzees. In HCV-infected chimpanzees increased spontaneous cytotoxicity was observed in CD94(high/dim) CD16(pos) and CD94(low) CD16(pos) subsets. By contrast, increased natural cytotoxicity receptor (NCR)- mediated degranulation after NKp30 and NKp44 triggering was demonstrated in the CD94(dim) CD16(neg) subset. Our findings suggest that spontaneous and NCR-mediated cytotoxicity are effector functions of distinct NK subsets in HCV-infected chimpanzees.


Asunto(s)
Linaje de la Célula/inmunología , Citotoxicidad Inmunológica , Hepacivirus/inmunología , Hepatitis C/inmunología , Células Asesinas Naturales/inmunología , Animales , Enfermedades del Simio Antropoideo , Degranulación de la Célula/efectos de los fármacos , Citometría de Flujo , Regulación de la Expresión Génica , Hepatitis C/patología , Hepatitis C/virología , Inmunofenotipificación , Interleucina-2/farmacología , Interleucinas/farmacología , Células Asesinas Naturales/clasificación , Células Asesinas Naturales/citología , Células Asesinas Naturales/efectos de los fármacos , Activación de Linfocitos/efectos de los fármacos , Proteína 1 de la Membrana Asociada a los Lisosomas/genética , Proteína 1 de la Membrana Asociada a los Lisosomas/inmunología , Subfamília D de Receptores Similares a Lectina de las Células NK/genética , Subfamília D de Receptores Similares a Lectina de las Células NK/inmunología , Receptor 2 Gatillante de la Citotoxidad Natural/genética , Receptor 2 Gatillante de la Citotoxidad Natural/inmunología , Receptor 3 Gatillante de la Citotoxidad Natural/genética , Receptor 3 Gatillante de la Citotoxidad Natural/inmunología , Pan troglodytes , Receptores de IgG/genética , Receptores de IgG/inmunología
8.
Clin Exp Immunol ; 180(2): 329-40, 2015 May.
Artículo en Inglés | MEDLINE | ID: mdl-25557528

RESUMEN

Memory B cells play a pivotal role in alloreactivity in kidney transplantation. Follicular T helper (Tfh) cells play an important role in the differentiation of B cells into immunoglobulin-producing plasmablasts [through interleukin (IL)-21]. It is unclear to what extent this T cell subset regulates humoral alloreactivity in kidney transplant patients, therefore we investigated the absolute numbers and function of peripheral Tfh cells (CD4(POS) CXCR5(POS) T cells) in patients before and after transplantation. In addition, we studied their relationship with the presence of donor-specific anti-human leucocyte antigen (HLA) antibodies (DSA), and the presence of Tfh cells in rejection biopsies. After transplantation peripheral Tfh cell numbers remained stable, while their IL-21-producing capacity decreased under immunosuppression. When isolated after transplantation, peripheral Tfh cells still had the capacity to induce B cell differentiation and immunoglobulin production, which could be inhibited by an IL-21-receptor-antagonist. After transplantation the quantity of Tfh cells was the highest in patients with pre-existent DSA. In kidney biopsies taken during rejection, Tfh cells co-localized with B cells and immunoglobulins in follicular-like structures. Our data on Tfh cells in kidney transplantation demonstrate that Tfh cells may mediate humoral alloreactivity, which is also seen in the immunosuppressed milieu.


Asunto(s)
Linfocitos B/inmunología , Rechazo de Injerto/inmunología , Inmunidad Humoral , Memoria Inmunológica , Trasplante de Riñón , Linfocitos T Colaboradores-Inductores/inmunología , Adulto , Anciano , Linfocitos B/fisiología , Línea Celular , Femenino , Rechazo de Injerto/patología , Rechazo de Injerto/prevención & control , Humanos , Terapia de Inmunosupresión/métodos , Interleucinas/inmunología , Masculino , Persona de Mediana Edad , Linfocitos T Colaboradores-Inductores/patología
9.
Child Psychiatry Hum Dev ; 45(4): 443-55, 2014 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-24186305

RESUMEN

Parental self-efficacy (PSE; parental self-perceived competence in parenting) is known to have considerable impact on parenting quality. Although PSE is particularly under pressure during the turbulent period of toddlerhood, most studies so far have focused on PSE in parents of older children. The current study presents the psychometric qualities of the Short Form of the Self-Efficacy for Parenting Tasks Index-Toddler Scale (SEPTI-TS). Parents from a normal (n = 282) and clinical sample (n = 27) of children filled in the SEPTI-TS, and other questionnaires concerning PSE, general self-evaluation, and psychological problems. Factor analysis resulted in a 26-item instrument, representing four domains of PSE with a strong factor structure and high reliability: nurturance, discipline, play, and routine. For this new Short Form of the SEPTI-TS, good face, discriminative, concurrent, and divergent validity were found. Cut-offs for normal PSE were provided. The Short Form SEPTI-TS enables identifying problematic PSE in specific domains of parenting during toddlerhood.


Asunto(s)
Relaciones Padres-Hijo , Responsabilidad Parental/psicología , Padres/psicología , Autoeficacia , Preescolar , Femenino , Humanos , Lactante , Masculino , Psicometría , Reproducibilidad de los Resultados , Apoyo Social , Estrés Psicológico/psicología , Encuestas y Cuestionarios
10.
J Viral Hepat ; 20(4): e78-81, 2013 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-23490393

RESUMEN

Achievement of a sustained virologic response (SVR) after peginterferon (PEG-IFN) and ribavirin (RBV) treatment is considered to be a marker for the cure of chronic hepatitis C virus (HCV) infection. Long-term follow-up of patients with SVR after treatment with a direct acting antiviral has not yet been described. We used a randomized placebo-controlled, double-blind, two-period phase 1b trial that was conducted in 40 HCV genotype 1 (treatment-naïve and treatment-experienced)-infected patients. Nineteen patients achieved SVR after treatment with the HCV protease inhibitor narlaprevir followed by PEG-IFN/RBV. In these patients, HCV-RNA tests were scheduled at 3, 6, 12 and 24 months after end of treatment. Patients were followed for a median of 27 months (range 15-32) after end of treatment with a median number of follow-up visits of 4 (range 3-8). All patients remained HCV-RNA negative over time. SVR achieved following narlaprevir and PEG-IFN/RBV-therapy was durable up to 32 months after the end of treatment.


Asunto(s)
Antivirales/administración & dosificación , Dipéptidos/administración & dosificación , Hepatitis C Crónica/tratamiento farmacológico , Interferón-alfa/administración & dosificación , Polietilenglicoles/administración & dosificación , Ribavirina/administración & dosificación , Sulfonas/administración & dosificación , Adulto , Anciano , Ciclopropanos , Método Doble Ciego , Quimioterapia Combinada/métodos , Femenino , Estudios de Seguimiento , Hepacivirus/aislamiento & purificación , Hepatitis C Crónica/virología , Humanos , Interferón alfa-2 , Leucina/análogos & derivados , Masculino , Persona de Mediana Edad , Placebos/administración & dosificación , Prolina/análogos & derivados , ARN Viral/sangre , Proteínas Recombinantes/administración & dosificación , Resultado del Tratamiento , Urea , Carga Viral
11.
J Viral Hepat ; 20(5): 322-7, 2013 May.
Artículo en Inglés | MEDLINE | ID: mdl-23565614

RESUMEN

HBeAg seroconversion in HBV patients is considered an important event. We determined precore (PC) and base core promoter (BCP) mutations in 137 HBeAg-positive nucleos(t)ide analogues (NA) treated patients by INNO-LiPA HBV PreCore assay (Innogenetics). The majority of patients with nongenotype A had PC/BCP mutants present at baseline (P = 0.02). During 29 months of therapy, 45 patients achieved HBeAg seroconversion. Probability of HBeAg seroconversion was higher in patients with PC and/or BCP mutants (P = 0.01). After HBeAg seroconversion, patients with BCP mutants had more HBeAg relapse (P = 0.07), and PC mutants less often achieved HBV DNA < 2000 IU/mL (P = 0.07).


Asunto(s)
Antivirales/uso terapéutico , Antígenos e de la Hepatitis B/sangre , Virus de la Hepatitis B/genética , Hepatitis B Crónica/tratamiento farmacológico , Mutación , Nucleósidos/uso terapéutico , Regiones Promotoras Genéticas , Adulto , Femenino , Genotipo , Virus de la Hepatitis B/aislamiento & purificación , Hepatitis B Crónica/virología , Humanos , Masculino , Persona de Mediana Edad , Recurrencia , Resultado del Tratamiento , Adulto Joven
12.
J Viral Hepat ; 20(3): 158-66, 2013 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-23383654

RESUMEN

As chronic hepatitis C patients with progressive disease can present themselves with normal ALT levels, more sensitive biomarkers are needed. MicroRNAs are newly discovered small noncoding RNAs that are stable and detectable in the circulation. We aimed to investigate the association between hepatocyte-derived microRNAs in serum and liver injury in patients with chronic hepatitis C. The hepatocyte-derived miR-122 and miR-192 were analysed in sera of 102 chronic HCV-infected patients and 24 healthy controls. Serum levels of miR-122 and miR-192 correlated strongly with ALT (R = 0.67 and R = 0.65, respectively, P < 0.001 for both). Median levels of miR-122 and miR-192 in HCV-infected patients were 23 times and 8 times higher as in healthy controls (P < 0.001 for both). Even within the HCV-infected patients with a normal ALT (n = 38), the levels of miR-122 and miR-192 were 12 times and 4 times higher compared with healthy controls (P < 0.001 for both). Multivariate logistic regression analyses showed that only miR-122 was a significant predictor of the presence of chronic HCV infection (P = 0.026). Importantly, miR-122 was also superior in discriminating chronic HCV-infected patients with a normal ALT from healthy controls compared with the ALT level (AUC = 0.97 vs AUC = 0.78, P = 0.007). In conclusion, our study confirmed that liver injury is associated with high levels of hepatocyte-derived microRNAs in circulation and demonstrated that in particular miR-122 is a sensitive marker to distinguish chronic hepatitis C patients from healthy controls. More sensitive blood markers would benefit especially those patients with minor levels of hepatocellular injury, who are not identified by current screening with ALT testing.


Asunto(s)
Biomarcadores/sangre , Hepatitis C Crónica/diagnóstico , MicroARNs/sangre , Adulto , Anciano , Alanina Transaminasa/sangre , Femenino , Hepatitis C Crónica/patología , Humanos , Hígado/patología , Masculino , Persona de Mediana Edad , Sensibilidad y Especificidad
13.
J Viral Hepat ; 19(2): e26-33, 2012 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-22239523

RESUMEN

Natural killer cells (NK) are one of the key players in the eradication and control of viral infections. Infections with the hepatitis B virus (HBV) may lead to persistence in a subgroup of patients, and impaired NK cell functions have been observed in these patients. Crosstalk with other immune cells has been shown to modulate the function of NK cells. We studied the functional crosstalk between NK cells and plasmacytoid dendritic cell (pDC) and its modulation by HBV. Healthy human peripheral blood-derived NK cells and pDC were purified and cocultured in the presence or absence of HepG2.2.15-derived HBV under various in vitro conditions. The functionality of NK cells was assessed by evaluation of activation markers, cytokine production and cytotoxicity of carboxyfluorescein succinimidyl ester-labelled K562 target cells by flow cytometry or immunoassays. Additionally, the crosstalk was examined using NK and pDC from patients with chronic HBV. The activation of NK cells in cocultures with pDC, as demonstrated by CD69, CD25 and HLA-DR, was not affected by the presence of HBV. Similarly, when cocultured with pDC, the cytotoxic potential of NK cells was not influenced by HBV. However, HBV significantly inhibited pDC-induced IFN-γ production by NK cells both in the presence and in the absence of CpG. As HBV did not affect cytokine-induced IFN-γ production by NK cells cultured alone, the suppressive effect of HBV on NK cell function was mediated via interference with pDC-NK cell interaction. In contrast to other viruses, HBV does not activate pDC-NK cell interaction but inhibits pDC-induced NK cell function. In parallel with NK cells of patients with chronic HBV, which show diminished cytokine production with normal cytotoxicity, HBV specifically suppressed pDC-induced IFN-γ production by NK cells without affecting their cytolytic ability. These data demonstrate that HBV modulates pDC-NK cell crosstalk, which may contribute to HBV persistence.


Asunto(s)
Células Dendríticas/inmunología , Virus de la Hepatitis B/inmunología , Virus de la Hepatitis B/patogenicidad , Células Asesinas Naturales/inmunología , Células Cultivadas , Técnicas de Cocultivo , Citocinas/metabolismo , Citotoxicidad Inmunológica , Humanos , Tolerancia Inmunológica , Activación de Linfocitos
14.
Eur Respir J ; 37(6): 1386-91, 2011 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-20884742

RESUMEN

The aims of this study were to assess the prevalence of iron deficiency in idiopathic pulmonary arterial hypertension (IPAH) and investigate whether oral iron supplementation has effects in iron-deficient patients. Iron parameters were measure for all IPAH patients attending our centre (VU University Medical Center, Amsterdam, the Netherlands) between May 2009 and February 2010. Iron data were related to clinical parameters, including 6-min walking distance (6MWD), and haemodynamic parameters measured during right heart catheterisation. In a subset of iron-deficient patients, the uptake of iron from the bowel was studied after administering oral iron for 4 weeks. Iron deficiency was found in 30 (43%) out of 70 patients. 6MWD was reduced in iron-deficient patients compared with iron-sufficient patients (mean±sd 390±138 versus 460±143 m; p<0.05) irrespective of the existence of anaemia. In a subset of 18 patients that received oral iron, ferritin levels were significantly increased, although eight patients only slightly increased their iron storage. This study shows that iron deficiency is frequently present in IPAH and is associated with a lower exercise capacity. The small response to oral iron in 44% of the treated patients suggests impaired iron absorption in these patients.


Asunto(s)
Hipertensión Pulmonar/epidemiología , Deficiencias de Hierro , Adulto , Anciano , Cateterismo Cardíaco , Suplementos Dietéticos , Prueba de Esfuerzo , Hipertensión Pulmonar Primaria Familiar , Femenino , Ferritinas/sangre , Humanos , Hierro/uso terapéutico , Masculino , Persona de Mediana Edad
15.
Dis Esophagus ; 24(5): 371-3, 2011 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-21166735

RESUMEN

Recently, a mouse model for Barrett's esophagus based on a zinc-deficient diet supplemented with deoxycholic bile acids has been published. The aim of this study was to attempt to reproduce these data and extend them by employing genetically modified mice and intraperitoneal iron supplementation. The study design encompassed six experimental groups (wild type, Apc-mutant and Smad4-mutant mice, with or without iron injections), with all animals fed with the zinc-deficient diet supplemented with deoxycholic bile acids. All treatments were started at 3-5 weeks of age (the majority [78%] at 5 weeks). Animals were scheduled for euthanasia at two distinct time points, namely at 3 and 6 months of age. All mice showed signs of considerable distress already 4 weeks after the start of the modified diets, and had to be euthanized before the first evaluation time point (mean age 9.3 weeks, range 5-15 weeks). No differences were observed between wild type and genetically modified mice, or between animals with or without iron supplementation. On histological examination, we could not detect any lesions (Barrett's esophagus-like or tumors) other than esophagitis. In the currently presented experimental settings, we were not able to reproduce the mouse model according to which Barrett's-like lesions could be detected in animals fed with the zinc-deficient diet supplemented with deoxycholic bile acids.


Asunto(s)
Esófago de Barrett/inducido químicamente , Colagogos y Coleréticos/administración & dosificación , Ácido Desoxicólico/administración & dosificación , Suplementos Dietéticos/efectos adversos , Modelos Animales de Enfermedad , Oligoelementos/deficiencia , Zinc/deficiencia , Animales , Esófago de Barrett/patología , Dieta/efectos adversos , Esofagitis/inducido químicamente , Esofagitis/patología , Hierro/administración & dosificación , Ratones , Ratones Mutantes , Reproducibilidad de los Resultados , Proteína Smad4/genética , Oligoelementos/administración & dosificación
16.
Am J Physiol Heart Circ Physiol ; 297(6): H2154-60, 2009 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-19801491

RESUMEN

The product of resistance, R, and compliance, C (RC time), of the entire pulmonary circulation is constant. It is unknown if this constancy holds for individual lungs. We determined R and C in individual lungs in chronic thromboembolic pulmonary hypertension (CTEPH) patients where resistances differ between both lungs. Also, the contribution of the proximal pulmonary arteries (PA) to total lung compliance was assessed. Patients (n=23) were referred for the evaluation of CTEPH. Pressure was measured by right heart catheterization and flows in the main, left, and right PA by magnetic resonance imaging. Total, left, and right lung resistances were calculated as mean pressure divided by mean flow. Total, left, and right lung compliances were assessed by the pulse pressure method. Proximal compliances were derived from cross-sectional area change DeltaA and systolic-diastolic pressure difference DeltaP (DeltaA/DeltaP) in main, left, and right PA, multiplied by vessel length. The lung with the lowest blood flow was defined "low flow" (LF), the contralateral lung "high flow" (HF). Total resistance was 0.57+/-0.28 mmHg.s(-1).ml(-1), and resistances of LF and HF lungs were 1.57+/-0.2 vs. 1.00+/-0.1 mmHg.s(-1).ml(-1), respectively, P<0.0001. Total compliance was 1.22+/-1.1 ml/mmHg, and compliances of LF and HF lung were 0.47+/-0.11 and 0.62+/-0.12 ml/mmHg, respectively, P=0.01. Total RC time was 0.49+/-0.2 s, and RC times for the LF and HF lung were 0.45+/-0.2 and 0.45+/-0.1 s, respectively, not different. Proximal arterial compliance, given by the sum of main, right, and left PA compliances, was only 19% of total lung compliance. The RC time of a single lung equals that of both lungs together, and pulmonary arterial compliance comes largely from the distal vasculature.


Asunto(s)
Hipertensión Pulmonar/etiología , Hipertensión Pulmonar/fisiopatología , Pulmón/irrigación sanguínea , Arteria Pulmonar/fisiopatología , Circulación Pulmonar , Tromboembolia/complicaciones , Resistencia Vascular , Adulto , Anciano , Presión Sanguínea , Cateterismo Cardíaco , Enfermedad Crónica , Adaptabilidad , Femenino , Humanos , Imagen por Resonancia Magnética , Masculino , Persona de Mediana Edad , Tromboembolia/fisiopatología , Factores de Tiempo , Adulto Joven
17.
Eur Respir J ; 34(2): 371-9, 2009 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-19282344

RESUMEN

Systemic sclerosis-associated pulmonary arterial hypertension (SScPAH) has a worse prognosis and response to pulmonary arterial hypertension (PAH) therapy than idiopathic PAH (IPAH). These differences have not yet been explained. Knowledge concerning histological pulmonary vasculopathy in SScPAH is limited in contrast to IPAH. Therefore, we explored patterns of vasculopathy in SScPAH compared with IPAH. Parameters of vasculopathy were assessed from lung tissue of eight PAH patients with limited cutaneous systemic sclerosis and 11 IPAH patients. Lung tissue was obtained at autopsy (n = 15), explantation (n = 3) and biopsy (n = 1). Pulmonary arterial/arteriolar intimal fibrosis was identified in all SScPAH patients and in three IPAH patients (p = 0.003). Fibrosis of pulmonary veins/venules was found in all SScPAH patients and in three IPAH patients (p = 0.003). In four SScPAH patients, fibrosis of veins/venules was focal and associated with capillary congestion as in pulmonary veno-occlusive disease (PVOD). Of the IPAH patients, 10 had unequivocal evidence of plexogenic arteriopathy compared with none of the SScPAH patients (p = 0.001). SScPAH is characterised by small vessel intimal fibrosis, which is associated with a PVOD-like pattern in some cases. This might explain its different clinical behaviour from IPAH. Small vessel intimal fibrosis may provide clues to elucidation of differences in pathogenetic mechanisms between the groups.


Asunto(s)
Hipertensión Pulmonar/complicaciones , Enfermedad Veno-Oclusiva Pulmonar/complicaciones , Esclerodermia Sistémica/complicaciones , Enfermedades de la Piel/complicaciones , Adulto , Autopsia , Biopsia , Femenino , Fibrosis , Humanos , Hipertensión Pulmonar/fisiopatología , Pulmón/fisiopatología , Masculino , Persona de Mediana Edad , Arteria Pulmonar/fisiopatología , Enfermedad Veno-Oclusiva Pulmonar/fisiopatología , Esclerodermia Sistémica/fisiopatología , Enfermedades de la Piel/fisiopatología
18.
Eur Respir J ; 34(3): 669-75, 2009 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-19720810

RESUMEN

We determined the physiological effects of exercise training on exercise capacity and quadriceps muscle function in patients with idiopathic pulmonary arterial hypertension (iPAH). In total, 19 clinically stable iPAH patients (New York Heart Association II-III) underwent a supervised exercise training programme for the duration of 12 weeks. Maximal capacity, endurance capacity and quadriceps function were assessed at baseline and after 12 weeks. In 12 patients, serial quadriceps muscle biopsies were obtained. 6-min walk distance and peak exercise capacity did not change after training. However, endurance capacity improved significantly after training, demonstrated by a shift of the anaerobic threshold to a higher workload (from 32+/-5 to 46+/-6 W; p = 0.003) together with an increase in exercise endurance time (p<0.001). Moreover, exercise training increased quadriceps strength by 13% (p = 0.005) and quadriceps endurance by 34% (p = 0.001). Training enhanced aerobic capacity of the quadriceps, by increasing capillarisation (1.36+/-0.10 to 1.78+/-0.13 capillaries per muscle fibre; p<0.001) and oxidative enzyme activity, especially of the type-I (slow) muscle fibres. No changes were found in cross-sectional area and fibre type distribution. Exercise training in iPAH improves exercise endurance and quadriceps muscle function, which is also reflected by structural changes of the quadriceps.


Asunto(s)
Atención Ambulatoria , Ejercicio Físico/fisiología , Hipertensión Pulmonar/fisiopatología , Hipertensión Pulmonar/rehabilitación , Adulto , Umbral Anaerobio/fisiología , Tolerancia al Ejercicio/fisiología , Femenino , Estudios de Seguimiento , Humanos , Hipertensión Pulmonar/patología , Masculino , Persona de Mediana Edad , Fuerza Muscular/fisiología , Músculo Cuádriceps/patología , Músculo Cuádriceps/fisiopatología , Resultado del Tratamiento
19.
Eur Respir J ; 32(1): 232-5, 2008 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-18591341

RESUMEN

The platelet-derived growth factor receptor inhibitor imatinib has demonstrated clinical and haemodynamical improvement in both animal models of pulmonary hypertension (PH) and patients with PH. It has been suggested that anti-proliferative effects on pulmonary vascular smooth muscle cells are responsible for these beneficial effects. The current study describes a patient with pulmonary arterial hypertension associated with a suspected pulmonary veno-occlusive disease. Treatment with imatinib resulted in rapid clinical improvement and decrease of ground-glass opacities and lobular septal thickening on high-resolution computed tomography. Based on these findings and on in vitro effects of imatinib on permeability of the endothelium, the authors hypothesise that the rapid clinical outcome is partly due to effects of imatinib on vascular integrity.


Asunto(s)
Piperazinas/uso terapéutico , Inhibidores de Agregación Plaquetaria/uso terapéutico , Enfermedad Veno-Oclusiva Pulmonar/tratamiento farmacológico , Pirimidinas/uso terapéutico , Benzamidas , Quimioterapia Combinada , Epoprostenol/uso terapéutico , Femenino , Humanos , Hipertensión Pulmonar/tratamiento farmacológico , Mesilato de Imatinib , Persona de Mediana Edad , Vasodilatadores/uso terapéutico
20.
Eur Respir J ; 31(4): 759-64, 2008 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-18094009

RESUMEN

In chronic obstructive pulmonary disease (COPD) patients, stroke volume response to exercise is impaired. The aim of the present study was to investigate whether 3 months of sildenafil treatment improves stroke volume and, if so, whether this improvement is related to the pulmonary artery pressure and translated into an improved exercise capacity. A total of 15 stable COPD patients (Global Initiative for Chronic Obstructive Lung Disease stage II-IV) underwent right heart catheterisation at rest and during exercise. Stroke volume was assessed by magnetic resonance imaging (MRI) at rest and during submaximal exercise in the supine position and compared with eight age-matched controls. Additionally, a cardiopulmonary exercise test and a 6-min walking distance test were performed. Exercise tests and MRI were repeated after 12 weeks of oral therapy with 50 mg sildenafil three times daily. Stroke volume in COPD patients was significantly lower than in healthy controls (62+/-12 versus 81+/-22 mL at rest and 70+/-15 versus 101+/-28 mL during exercise). Pulmonary hypertension (PH) was diagnosed in nine patients and was absent in six. Treatment with sildenafil had no effect on stroke volume or exercise capacity. Although the stroke volume was lower in COPD patients with associated PH in comparison with non-PH patients, there was no difference in treatment response between both groups. In the present group of 15 chronic obstructive pulmonary disease patients, a reduced stroke volume was found at rest and during exercise. Neither stroke volume nor exercise capacity were improved by 3 months of sildenafil therapy.


Asunto(s)
Hipertensión Pulmonar , Piperazinas/farmacología , Enfermedad Pulmonar Obstructiva Crónica/complicaciones , Volumen Sistólico/efectos de los fármacos , Sulfonas/farmacología , Vasodilatadores/farmacología , Anciano , Estudios de Casos y Controles , Prueba de Esfuerzo/métodos , Femenino , Humanos , Hipertensión Pulmonar/complicaciones , Hipertensión Pulmonar/tratamiento farmacológico , Hipertensión Pulmonar/fisiopatología , Masculino , Persona de Mediana Edad , Piperazinas/uso terapéutico , Enfermedad Pulmonar Obstructiva Crónica/tratamiento farmacológico , Enfermedad Pulmonar Obstructiva Crónica/fisiopatología , Purinas/farmacología , Purinas/uso terapéutico , Citrato de Sildenafil , Volumen Sistólico/fisiología , Sulfonas/uso terapéutico , Vasodilatadores/uso terapéutico
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA